



## **ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013**

March 13, 2013

SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25<sup>th</sup> Annual ROTH Conference on Tuesday, March 19, 2013, at 10:00 a.m. Pacific Time at The Ritz-Carlton in Laguna Niguel.

A live webcast of ACADIA's presentation will be accessible on the company's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and an archived recording will be available on the website through April 2, 2013.

### *About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA. ACADIA maintains a website at [www.acadia-pharm.com](http://www.acadia-pharm.com) to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

### *Forward-Looking Statements*

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, either alone or with a partner, including clinical trials, and the benefits to be derived from ACADIA's product candidates, in each case including pimavanserin. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2012 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

*ACADIA Pharmaceuticals Inc.*

*Thomas H. Aasen, Executive Vice President,  
Chief Financial Officer and Chief Business Officer  
858-558-2871*